Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Non-Valvular Atrial Fibrillation
Sort By
Newest First
Sign in
1 / 1
1 / 1
Real-World Study
New Real-World Study Finds Long-Term XARELTO® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli
Janssen Pharmaceutical Companies
PR-M05-18-NI-101
May 28, 2018
